Patients With ALS and Other Motor Disorders Will be Treated With Mesenchymal Cell Exosome Solution

Patients With ALS and Other Motor Discorders Will be Treated With Mesenchymal Cell Exosome Solution

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07105371

Enrollment

Registered

2025-08-05

Start date

2024-07-14

Completion date

2025-03-14

Last updated

2025-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Motor Disorders

Keywords

exosomes, secretome, ALS, Kennedy disease, Congenital Myasthenic Syndrome, Lewy body dementia

Brief summary

Patients with ALS and other Motor Discorders will be treated with mesenchymal cell exosome solution.

Detailed description

Single Arm non-controlled study. Patients are prospectively evaluated then treated. Outcomes are tracked after treatment.

Interventions

BIOLOGICALAlloEx exosomes

This is an intranasal treatment of exosomes derived from mesenchymal stem cells.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients will need a diagnosis established by a neurologist. Patients must be able to provide informed consent, or have a guardian who does. They must be able to travel to the site of treatment.

Exclusion criteria

* Patients were excluded from the trial if they were pregnant or had active cancer at the screening consultation.

Design outcomes

Primary

Measure	Time frame
ALSFRS-R Results	from enrollment until 6 months after treatment

Countries

Antigua and Barbuda

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026